Biomarkers in drug discovery and development
Renal cell carcinoma: the search for a reliable biomarker - Farber - Translational Cancer Research
Renal cancer biomarkers: the promise of personalized care | BMC Medicine | Full Text
Cabozantinib Slows Progression of Rare Kidney Cancer - NCI
Prognostic and predictive biomarkers in Renal Cell Carcinoma. | Download Table
Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers
The Hunt for Urinary Biomarkers to Diagnose Kidney Cancer - Johns Hopkins Medicine
Diseases | Free Full-Text | Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review
Mapping the immune environment in clear cell renal carcinoma by single-cell genomics | Communications Biology
Comprehensive molecular characterization of clear cell renal cell carcinoma | Nature
Frontiers | Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review: Molecular Therapy - Nucleic Acids
Biomarkers in renal cell carcinoma: Are we there yet? - ScienceDirect
Kidney Cancer: Recent Advances and Future Directions | Journal of Clinical Oncology
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature - ScienceDirect
Frontiers | The Identification of Immunological Biomarkers in Kidney Cancers
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
What is a Biomarker? | Lippincott NursingCenter
Self-Referenced Synthetic Urinary Biomarker for Quantitative Monitoring of Cancer Development | Journal of the American Chemical Society
Determinants of renal cell carcinoma invasion and metastatic competence | Nature Communications
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma | Journal of Experimental & Clinical Cancer Research
